Curve Therapeutics’ Post

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

📢 Funding News: £35 Million Series A Financing 📢 Today, we announce our Series A financing round led by Forbion, alongside our founding investors SV Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). The funds will be used to advance our small molecule somatic expansion inhibition therapy for Huntington’s disease. Our lead programme, MutSβ inhibitor is expected to enter the clinic in 2026. In connection with the financing, we welcome Rogier Rooswinkel, General Partner at Forbion to the LoQus23 Board of Directors. At LoQus23, we are investigating small molecule drugs that could stop #DNAinstability and slow #neurodegeneration in #HuntingtonsDisease. We look forward to progressing our pipeline with the support of our investors, so make sure you’re following LoQus23 Therapeutics Ltd on LinkedIn to stay up to date. 👉 Visit our new website to read the press release and find out more by using the link in the comments below. #financing #venturecapital #drugdevelopment #UKbiotech

It's no secret that I'm a big believer that #biotech is the investment wave of the 2020s. So, am I surprised that CG Oncology's IPO soared by 96% on its first day? Well, a little! Some #investors have been slow to adopt the biotech wave—especially when it's a brand-new IPO. But CG's success could point to increased (and much-deserved) interest in the field. Time will tell if CG Oncology can live up to these expectations. But one thing is clear: biotech #investments are growing in popularity. And I expect that trend to continue for at least the next several years. https://loom.ly/GNf7vvQ

🚀 Exciting Insights from Apogee Therapeutics' Journey to IPO 🧬 As we reflect on the remarkable journey of Apogee Therapeutics, it’s a privilege to share some key insights from their conversation with Michael Henderson, CEO of Apogee Therapeutics, and Kyle LaHucik, Senior Reporter at Endpoints News. In a market where biotech's have tread cautiously, Apogee Therapeutics's bold leap into a $300 million IPO focused on immune and inflammatory sectors stands out. Here's a glimpse into the discussion: 🌟 Why an IPO in Such a Challenging Market? Apogee didn't just aim for larger markets; they were determined to capitalize on big ideas. Harnessing a first-mover advantage was crucial, and when asked by investors how they could accelerate their pace, Apogee's answer was clear - from draft registration to IPO in just four months! 💡 The Heat in the I&I Space: Despite warnings from bankers about the difficulty of breaking into big markets with substantial risks, Apogee's compelling science and preclinical investments set them apart. 🔍 Facing the Big Question: "Why not wait until clinical trials?" Many have been burned before, leading to skepticism. Apogee’s response? A solid strategy and a transparent path forward. 🤝 Securing Cross-Over Investors: After a successful Series B, raising $149 million in 2022, Apogee strategically brought over cross-over investors, ensuring rapid and significant backing for the IPO. 🎯 Targeting Clinical Validation to De-Risk Early: The goal is crystal clear – to achieve clinical validation early and establish clear differentiation, adding undeniable value in the I&I space. 🧐 Considering a Reverse Merger? Yes, Apogee did. It’s vital for every company to explore all avenues, and with robust science and strong investor support, all options were on the table. 💥 From Stealth to Spotlight: Initially targeting $200M, Apogee's early TTW campaign was pivotal. Being in stealth mode meant needing to amplify their message, which they did effectively. As we witness Apogee's journey, it’s a masterclass in strategic planning, investor relations, and scientific innovation. Here's to their continued success in revolutionizing the biotech landscape! #jpm2024 #innovation #strategy #biotech

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Two SPAC’d biotechs raise additional money as Bihua Chen’s blank check closes $184M IPO: The post-SPAC life isn’t all too great for most biotech companies — or those in other industries, for that matter. But some drug developers that went the blank-check route have found greener pastures in recent months, with two of them announcing large financings this week. Bihua Chen This is amid a second biotech SPAC from Bihua Chen, founder of Cormorant Asset Management. Known as Helix Acquisition Corp. II $HLXB, the SPAC closed a $184 million initial public offering on Wednesday. It will hunt for a biotech or other healthcare business to combine with after Helix I found success with MoonLake Immunotherapeutics. As for the two SPAC’d biotechs, bladder cancer gene therapy company enGene nabbed $200 million in a private placement at a 31% premium to its Tuesday closing price, while non-statin cardiovascular company NewAmsterdam Pharma priced a $175.3 million public offering on Tuesday evening. The raises follow a string of nine-figure financings for public biotechs in recent months, many in advance of or shortly after big data readouts. For enGene and NewAmsterdam, which went public via SPAC in November 2023 and November 2022, respectively, the raises mark a positive in the relatively bleak SPAC universe. The SPAC market “has cratered due to the deep underperformance of pandemic-era de-SPACs,” Oppenheimer bankers wrote in a 2023 review last month. Nine biopharma companies opted for a SPAC in 2023 compared to 21 in 2021, per the report. A few positive signals have emerged for the alternative financing vehicle, lately, though: Chen’s second SPAC (which originally set out for $100 million), and AbbVie’s $8.7 billion plans for Cerevel Therapeutics might serve as the best SPAC combination exit in industry history. enGene The $200 million raise for enGene, which is more than the $138 million in proceeds from its SPAC deal, comes as the Boston and Montreal non-viral gene therapy maker runs a pivotal study of its candidate for certain forms of non-muscle invasive bladder cancer, or NMIBC. The money gives enGene runway into 2027, and investors appeared happy: Shares of the biotech $ENGN skyrocketed 91% before Wednesday’s opening bell. The NMIBC field is riding a wave of momentum. CG Oncology, which is also in Phase III, kicked off the 2024 IPO class with a 95% pop in its first day of trading last month. Meanwhile, ImmunityBio inked up to $320 million in financing last month as it awaits an April PDUFA following an FDA rejection last year. And UroGen, which started its rolling NDA submission last month, raised $120 million on the back of Phase III data last summer. Jason Hanson enGene combined with a SPAC sponsored by Forbion, a European investor that has seen… #lucidquest #genetherapy #celltherapy

🚀 Is the biotech fundraising drought finally over? January's numbers say YES – with over $6 billion raised by visionary drug developers! 🌟 Let's celebrate these incredible milestones together: 🎉 Huge congrats to CG Oncology for their stellar $380 million IPO, skyrocketing from $19 to $43 per share! 🍄 And a round of applause for Lykos Therapeutics (formerly MAPS PBC), blazing trails with a groundbreaking $100 million series A, fueling the psychedelic revolution with style! 💡 Eyconisa, an Ascendis Pharma spin out, wows with a dazzling $150 million series A, backed by powerhouse investors like Frazier Life Sciences, RA Capital Management, venBio, and HealthQuest Capital! 💰 Cour Pharmaceuticals Development Co., Inc. joins the party with a bang, closing a remarkable $105 million series A, led by Lumira Ventures and Alpha Wave Global! 🔥 ArriVent Biopharma stuns the market with a $175 million IPO, surpassing expectations and setting a new standard for success! And although it was in February I have to mention Kyverna Therapeutics's jaw-dropping $319 million IPO – smashing their goal and pointing towards a future of transformative autoimmune cell therapy! With these groundbreaking achievements, can we finally say good times are ahead? It's about time! 😎💫 #BiotechRevolution #InnovationUnleashed #biotech #future

Today on the Business of Biotech, molecular biologist-turned-Chief Business Officer Neela Patel and academic-turned-founder of newly-formed Bonum Therapeutics John Mulligan, Ph.D. pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, Inc., which was fueled by a high-profile asset sale to Roche. Listen in as Neela and John share how the deal got done, how Good turned to Bonum, and where the company's taking its platform next. Listen and subscribe here: https://lnkd.in/edtyEWsF

Gene&Cell Therapy >> Two SPAC’d biotechs raise additional money as Bihua Chen’s blank check closes $184M IPO: The post-SPAC life isn’t all too great for most biotech companies — or those in other industries, for that matter. But some drug developers that went the blank-check route have found greener pastures in recent months, with two of them announcing large financings this week. Bihua Chen This is amid a second biotech SPAC from Bihua Chen, founder of Cormorant Asset Management. Known as Helix Acquisition Corp. II $HLXB, the SPAC closed a $184 million initial public offering on Wednesday. It will hunt for a biotech or other healthcare business to combine with after Helix I found success with MoonLake Immunotherapeutics. As for the two SPAC’d biotechs, bladder cancer gene therapy company enGene nabbed $200 million in a private placement at a 31% premium to its Tuesday closing price, while non-statin cardiovascular company NewAmsterdam Pharma priced a $175.3 million public offering on Tuesday evening. The raises follow a string of nine-figure financings for public biotechs in recent months, many in advance of or shortly after big data readouts. For enGene and NewAmsterdam, which went public via SPAC in November 2023 and November 2022, respectively, the raises mark a positive in the relatively bleak SPAC universe. The SPAC market “has cratered due to the deep underperformance of pandemic-era de-SPACs,” Oppenheimer bankers wrote in a 2023 review last month. Nine biopharma companies opted for a SPAC in 2023 compared to 21 in 2021, per the report. A few positive signals have emerged for the alternative financing vehicle, lately, though: Chen’s second SPAC (which originally set out for $100 million), and AbbVie’s $8.7 billion plans for Cerevel Therapeutics might serve as the best SPAC combination exit in industry history. enGene The $200 million raise for enGene, which is more than the $138 million in proceeds from its SPAC deal, comes as the Boston and Montreal non-viral gene therapy maker runs a pivotal study of its candidate for certain forms of non-muscle invasive bladder cancer, or NMIBC. The money gives enGene runway into 2027, and investors appeared happy: Shares of the biotech $ENGN skyrocketed 91% before Wednesday’s opening bell. The NMIBC field is riding a wave of momentum. CG Oncology, which is also in Phase III, kicked off the 2024 IPO class with a 95% pop in its first day of trading last month. Meanwhile, ImmunityBio inked up to $320 million in financing last month as it awaits an April PDUFA following an FDA rejection last year. And UroGen, which started its rolling NDA submission last month, raised $120 million on the back of Phase III data last summer. Jason Hanson enGene combined with a SPAC sponsored by Forbion, a European investor that has seen recent M&A successes with Aiolos Bio, Inversago… #lucidquest #genetherapy #celltherapy

We’re already feeling the impact of misguided #InflationReductionAct policies: Since 2021, venture capital investments in biopharma have dropped by 50% and IPOs for biopharma firms by 70% – with an outsized impact on investments targeting cancer treatments. New analysis from research firm Vital Transformation warns of further decline if lawmakers act on plans to expand government price controls. Read more here: https://lnkd.in/epwAjx2r

This article uncovers the considerations of when and how to consider raising additional capital to support clinical development. Explore the current market conditions, implications for biotech series B fundraising, and company strategies to consider here: https://lnkd.in/evWcyvP7 #biotechseriesb #seriesbfunding #biotechstrategy #biotechmarket #biotechcompany #lifescience #lifescivc